Close
Digital Health & Ai Innovation summit 2026
APE 2026

Perspectives from the AHA on Medicare Advantage Regulation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Konica Minolta and deepc AI Partnership...

Konica Minolta Healthcare Americas and deepc have formed a...

Medtronic Wins FDA Clearance for MiniMed...

Medtronic has received U.S. Food and Drug Administration (FDA)...

Novartis Plans its Fourth US Radioligand...

Novartis, which is a world-leading innovative medicines company, has...

In response to a request for details on the Medicare Advantage programme, the AHA recently provided comments to the Centers for Medicare & Medicaid Services. In its letter, the AHA expressed concerns about specific Medicare Advantage organisations’ practises and policies that limit or postpone access to care; it also provided relevant factors for health equity, behavioural health access, and post-acute care facilities; it outlined implications for the program’s continued enrolment growth; and it highlighted the special value that incorporated health systems offer to Medicare Advantage beneficiaries. Furthermore, the AHA offered a number of concrete recommendations that one feels are required to hold Medicare Advantage firms accountable for complying with the law, safeguarding beneficiaries from damage, and guaranteeing the viability of the Medicare programme.

Latest stories

Related stories

Konica Minolta and deepc AI Partnership Expands Exa Platform

Konica Minolta Healthcare Americas and deepc have formed a...

Medtronic Wins FDA Clearance for MiniMed Go Smart MDI System

Medtronic has received U.S. Food and Drug Administration (FDA)...

Novartis Plans its Fourth US Radioligand Therapy Facility

Novartis, which is a world-leading innovative medicines company, has...

Tempus-NYU Langone Collaboration Advances Precision Oncology

Tempus and NYU Langone Health have signed a multi-year...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »